Cyclosporin in Wegener's granulomatosis with renal failure Sir: In 1987 we presented in this journal the case history of a patient with Wegener's granulomatosis, in whom remission of the disease was achieved with cyclosporin.' Now, after more than three years' treatment with this immunosuppressive drug no further activity of the disease has occurred. Although we stated that cyclophosphamide is still the drug of first choice in the treatment of Wegener's granulomatosis, this positive experience persuaded us to start cyclosporin treatment in another patient with Wegener's granulomatosis resistant to conventional treatment. As the effect of cyclosporin in this patient was even more impressive than it had been in the previous subject we feel it is worth reporting this case history.
In 1982 a 72 year old women was admitted to our hospital for evaluation of cough, rhinorrhoea, fever, and fatigue. Laboratory tests showed a raised erythrocyte sedimentation rate (ESR) of 122 mm/h, thrombocytosis (platelets 625 x 10/l), and normal renal function. An x ray examination of the chest and sinus showed no abnormalities. Histopathological examination of a biopsy specimen of the nasopharynx, however, showed destructive granulomatous reaction with necrotising vasculitis, characteristic of Wegener's granulomatosis. Consequently, treatment with cyclophosphamide (100 mg/day) and prednisone (30 mg/day) was started. ,umol/l; propionic acid 13 (0-31) ,umol/l; n-butyric acid 3-4 (0-9) Wmol/l; n-valeric acid 3-6 (0-18) ,umol/l. There were no significant differences between normal and rheumatoid synovial fluids. Thus it seems that the direct action of anerobic bacteria-for example, Clostidium perfringens and others, which produce short chain fatty acids, is excluded. Although doses may indeed be to some extent based on tradition and anecdote, in such a capricious and visually devastating condition it is anecdotal exceptions to which attention must be directed if the opportunity to prevent visual loss is to be taken.
The fact that the 'high dose' group had fewer episodes of relapse than the 'low dose' group, but still suffered a significant therapeutic failure rate, implies that even higher dose regimens should be considered. Ophthalmologists usually use much higher doses of steroid, at least initially, when treating patients who present with the visual sequelae of giant cell arteritis.2 Although quite probably most cases of giant cell arteritis might be managed with a lower dose even than
